XOMA Announces Pricing of $40.0 Million Registered Offering of Common Stock and Warrants Dec 09, 2014 9:00am EST
XOMA Highlights Recent Achievements and Reports Financial Results for the Third Quarter of 2014 Nov 06, 2014 4:01pm EST
XOMA Initiates Pivotal Phase 3 Gevokizumab Study in Patients With Pyoderma Gangrenosum Nov 04, 2014 9:01am EST
XOMA to Announce Third Quarter 2014 Financial Results and Host Webcast on November 6 Oct 27, 2014 2:49pm EDT
The Texas A&M University System and XOMA License Innovative Manufacturing Technology Oct 06, 2014 1:00pm EDT
XOMA Initiates U.S. Clinical Trial of Gevokizumab in Patients With Behcet's Disease Uveitis - EYEGUARD(TM)-US Sep 30, 2014 4:05pm EDT
XOMA Highlights Recent Achievements and Reports Financial Results for Second Quarter 2014 Aug 07, 2014 4:01pm EDT
